Introduction
Despite advancements in many facets of neonatal intensive care, the outcomes for infants with hypoxic-ischemic brain injury (HIE) remain poor. Fifteen to twenty-five percent of infants with severe HIE die and 25-30% of survivors develop major long-term disabilities. In the two recently published trials of selective or total body cooling in infants with HIE, the incidence of death or neurological disability in the untreated group ranged from 62 to 68%. 1, 2 The treatment of infants with HIE is generally supportive and includes resuscitation techniques that follow the latest Neonatal advanced life support (NALS) guidelines, 3 attention to glucose, fluid and electrolyte homeostasis, maintenance of PaCO 2 within a normal range, correction of hypotension and treatment of seizures. A wide variety of neuroprotective strategies has been studied in experimental animals and infants with HIE. These include fluid restriction, prophylactic phenobarbital, oxygen-free radical scavengers or antagonists, excitatory amino-acid antagonists, nitric oxide synthase antagonists, calcium channel blockers, magnesium, N-methyl-D-aspartate (NMDA) receptor blockade, strategies to reduce cerebral edema (dexamethasone, furosemide, hyperventilation and mannitol) and hypothermia. Despite some initially promising results with some of these strategies (mostly in experimental animals), only hypothermia appears to be a safe and effective intervention. 4, 5 Interest in cooling the whole body or a body part can be traced back for thousands of years. However, it was not until the late 1940s that Miller et al. 6 made the observation that newborn animals tolerated anoxia longer if their body temperature was reduced. Between 1959 and 1972, 288 term or near-term infants were cooled as an adjunct to standard resuscitation. 7 Cooling was begun if there was no response to standard resuscitation practices at 5 minutes of age. Although mortality was reduced, there was no systematic neurological follow-up of cooled infants compared with a control group. Clinical interest in cooling babies diminished as reports about the adverse effects of hypothermia in preterm infants began to appear. Three randomized clinical trials by Silverman 8 published between 1958 and 1964 demonstrated that preterm infants reared in warm conditions had better rates of survival than those nursed in hypothermic conditions. Unfortunately, there was no systematic follow-up of survivors, so it is not known whether infants whose body temperature was kept in a cooler range may have had better long-term neurological outcomes. In 1997, Gunn et al. 9 demonstrated that selective head cooling of near-term fetal sheep reduced secondary cytotoxic edema and reduced cortical infarction and neuronal loss. In 1998, the same investigators demonstrated the safety of prolonged hypothermia in a study of 22 newborns. 10 To date only three randomized clinical trials of therapeutic hypothermia in the neonate have been published; however, several more trials are underway. This study will review the rationale for therapeutic hypothermia and the results of the three randomized clinical trials published to date.
Etiology and timing of brain injury in the full-term infant Cerebral palsy (CP) is most commonly thought of as a disease of the premature infant. However, approximately 50% of CP occurs in term infants of normal birth weight, with an overall prevalence of 1-2.4 per 1000 live births. 11 CP is a heterogeneous disorder, the common phenotypic expression resulting from a variety of pathologic processes, which may occur during the antenatal, acute intrapartum and postnatal periods.
Although the data regarding the timing of brain injury in full-term infants is somewhat controversial, the preponderance of evidence suggest that 70-80% of CP is in fact owing to events occurring during the antenatal course. 12, 13 In 2001, Croen demonstrated that congenital malformations were significantly more common in infants with CP when compared to controls. 14 Furthermore, distinct genetic mutations have been described in a small portion of term infants with CP. 15 There is an increased risk of CP associated with multiple gestation pregnancies, even after controlling for birth weight, particularly when there is in-utero demise of a co-twin or co-triplet. 16 Maternal or placental thrombotic disorders may also increase the risk for neonatal stroke and subsequent development of CP. Thrombotic vasculopathy of the placenta may be associated with acute and chronic electronic fetal monitoring abnormalities, cord pH less than 7.1 and increased nucleated red blood cells (NRBCs), 17 which may lead to the misdiagnosis of acute birth asphyxia. More recent studies have also implicated Factor V Leiden mutation as a potential risk factor for the development of perinatal stroke. 18, 19 Over the past several years, a multitude of publications have linked intrauterine infection and inflammation with the development of CP. In term and near-term infants, clinical markers of maternal infection were associated with a ninefold increase in the risk of spastic CP. 20 Notably, the authors found that most of the affected infants were not delivered following prolonged rupture of membranes and did not have recognizable signs of infection during the newborn period. Intrauterine exposure to infection is associated with meconium aspiration, low Apgar score, need for resuscitation and a risk of neonatal seizures, all of which are characteristics, which may easily be attributed to birth asphyxia. 20 Several postnatal events have been implicated in the development of CP, including sepsis, severe hypotension, persistent hypoxemia, hypocapnea, intracranial hemorrhage, hypoglycemia and hyperbilirubinemia. In the majority of these infants, there is a normal neurologic examination during the neonatal period and the underlying brain injury may not become clinically apparent for several months.
It is, however, the central nervous system (CNS) injury resulting from acute, intrapartum events, which is the subject of most controversy, both from a medicolegal point of view, but more importantly in the context of determining which infants may benefit from neuroprotective therapies in the immediate postnatal period. In 2001, Hagberg et al. 11 reported that only 36% of CP could be attributed to prenatal origins, and intrapartum events were likely responsible for most cases. Similarly, Cowen et al. 21 investigated fullterm infants with neonatal encephalopathy utilizing magnetic resonance imaging (MRI) scans and post-mortem examinations to distinguish between lesions acquired antenatally and those which developed in the intrapartum and early postpartum period. They determined that the vast majority of patients had evidence of acute intrapartum insult; only 3% had evidence of an antenatal injury. It is important to note, however, that selection of infants for this study was based upon clinical signs that were likely the result of problems arising during labor and delivery. Therefore, this subgroup of infants may be over-represented in their results. The majority of the literature, however, continues to suggest that only 5-20% of CP in term infants is the result of intrapartum asphyxia. Further evidence supporting this concept is that despite continuing drops in perinatal deaths, intrapartum injuries and technological advancements in perinatal care, there has been no net decrease in the occurrence of CP among full-term babies. 12, 22, 23 Deciphering the role of birth asphyxia in the development of long-term neurologic impairment is complicated by the difficulty in establishing the diagnosis of asphyxia itself. The diagnosis must be inferred from clinical signs, including abnormal fetal monitoring, persistently low Apgar scores, evidence of systemic acidosis and other laboratory markers. However, not one of these signs alone is specific for birth asphyxia as demonstrated by Paneth. 24 Furthermore, many infants whose intrapartum course is consistent with asphyxia also have additional significant prenatal risk factors for the development of CP such as intrauterine infection and coagulopathies. 25 Perlman et al., 26 proposed the use of a combination of clinical markers, specifically the presence of umbilical artery acidosis, the need for delivery room intubation and the 5 min Apgar score as a way of assessing the likelihood of neurologic complications. They found that infants who met all of these criteria were 340-fold more likely to develop seizures with an 80% positive predictive value, a sensitivity of 80% and a specificity of 98.8%. Some of the more common clinical markers, which may be helpful in determining the timing of brain injury in the full-term infant, are discussed below.
Fetal acidosis
Umbilical artery pH of less than 7 reflects severe, pathologic acidemia with an increased risk of neurologic sequelae. 27 According to a study by Goldaber et al., 28 a cord pH of less than 7.0 is present in less than 0.3% of all deliveries. However, the vast majority of these children do not have long-term neurologic sequelae. In a study of 47 infants who had severe fetal acidemia requiring intensive care, only eight developed hypoxic ischemic encephalopathy or seizures. 29 Similarly, in a study by Kirkendall, only 8.6% of infants with severe acidosis in the umbilical artery were found later to have evidence of brain injury. 30 In 2005, Livrejsin et al., 31 published similar findings, demonstrating that 8% of full-term, acidemic infants went on to develop seizures, however, there was no statistically significant association between a cord pH of less than 7 and adverse long-term outcomes. The reason that pH less than 7.0 is such a poor predictor of outcome is that many of those infants had a predominantly, respiratory acidosis rather than a metabolic acidosis.
Apgar score
Despite Dr Apgar's original intent, the Apgar score has been inappropriately used as a predictor of future neurologic outcome. 32, 33 A retrospective analysis by Casey concluded that the 5 min Apgar score remains a valid predictor of neonatal mortality, but is not a reliable predictor of long-term impairment. 34 Studies have demonstrated that the 5 min Apgar score does not correlate with cord pH, and therefore the presence of a low score is not indicative of asphyxia, as a high score does not ensure a favorable outcome. In fact, 75% of children with CP had normal 5 min Apgar scores at age 5 min. 35 Cardiac compressions in the delivery room The need for cardio pulmonary resuscitation (CPR) in the delivery room, as defined by chest compressions with or without medications, significantly increases the risk for abnormal neurologic outcomes. The risk is even greater if the need for CPR is associated with fetal acidosis. A study of 69 full-term infants requiring CPR in the delivery room revealed that 25 of 28 infants with associated severe fetal acidemia went on to develop abnormal neurologic outcomes as compared to only four of 41 infants requiring CPR who had a cord pH greater than 7.00. 36 
Hematologic markers
The presence of large numbers nucleated red blood cells (NRBCs) in cord blood or a venous sample postnatally has been suggested an indicator of previous hypoxemia. 37 After oxygen deprivation, there is increased production and release of erythropoietin, resulting in an increase in the proportion of immature, NRBCs in the circulation. Additionally, hypoxia-induced splenic injury may result in impaired clearance of these immature cells from the circulation. The NRBCs count rises within 12-24 hours after hypoxia. Phelan and Korst 38, 39 demonstrated that neurologically impaired infants had significantly more NRBCs than normal non-asphyxiated newborns. These investigators also demonstrated the importance of NRBCs clearance time, that is the length of time from birth until the disappearance of NRBCs from circulation. An initial elevated NRBCs count combined with a NRBCs clearance time of greater than 80 hours may be particularly helpful in identifying asphyxiated neonates. This concept is important because normal, non-asphyxiated infants may have elevated NRBCs counts from a variety of causes. 40 Hematologic dysfunction resulting from sustained acidosis and/ or hypoxia and often results in thrombocytopenia. Multiple studies have examined whether the presence of thrombocytopenia can provide information regarding the timing of brain injury. The results suggest that although thrombocytopenia may be associated with both acute and chronic hypoxic ischemic injury, a platelet count less than 100 000/ml within 5 days of birth is more likely to reflect an antenatal rather than acute intrapartum insult. 41 
Systemic organ injury
The adaptive response of the fetus following interruption of umbilical blood flow is a redistribution of cardiac output to preserve central nervous system (CNS) perfusion; therefore, the presence of multisystem organ dysfunction is often considered supportive evidence for the diagnosis of acute birth asphyxia. Multiple prospective studies have demonstrated that 60-80% of term, asphyxiated neonates exhibited evidence of single-or multisystem organ impairment in addition to their CNS injury. 42, 43 When faced with a case of possible birth asphyxia, clinicians often look to the liver and kidneys, for additional evidence of generalized hypoxic-ischemic insult. Renal dysfunction is currently the best systemic marker of potential brain injury and therefore oliguria, in the context of an abnormal neurologic exam, is often indicative of a poor neurologic prognosis. 44 However, not all infants with asphyxia will demonstrate systemic organ dysfunction, particularly if the acute neurologic injury occurs so quickly that there has not been sufficient time for the shunting of blood to occur. In fact, up to 10% of asphyxiated infants who have normal urine output, may have moderate to severe encephalopathy. 45 Neuroimaging Advances in neuroimaging, particularly magnetic resonance imaging (MRI), have aided in establishing the timing of brain injury in term infants. Early brain edema reflects recent insult. Reduced motion of water in diffusion-weighted MRI can be seen 24 h after the injury. Between 24 h and 7 days, hyperintensity of the gray matter may be evident and magnetic resonance spectroscopy often reveals elevated lactate levels. Later imaging findings include thinning of the cortex and decreased white matter as atrophy ensues. The postnatal evolution of changes over time is usually indicative of acute intrapartum asphyxia, whereas macroscopic abnormalities in the immediate postnatal period are commonly associated with a chronic antenatal insult. [46] [47] [48] Numerous criteria have been put forth to establish that an acute intrapartum event is sufficient to cause cerebral palsy. These criteria are obviously intended to make the diagnosis of asphyxia retrospectively, after spastic CP is evident. However, the recognition of infants at risk for the potential development of CP following a suspected hypoxic-ischemic event during the birthing process is most critical. With the advent of promising neuroprotective therapies for asphyxiated infants, the ability to rapidly and accurately identify those infants who would most benefit from them is paramount.
Pathogenesis and phases of hypoxic ischemic encephalopathy Hypoxic-ischemic encephalopathy (HIE) is a subset of neonatal encephalopathy that manifests following the disruption of Cerebral blood flow (CBF) and oxygen delivery in the term or near-term infant. The principal pathogenetic mechanism of HIE is interruption of placental blood flow and gas exchange. 50 The degree of CBF impairment caused by this insult dictates the timing and mode of cell death, as well as the ensuing degree and type of brain injury. The processes, contributing factors and outcomes of HIE are discussed herein.
The pathophysiology of HIE begins with the initial hypoxicischemic insult and unfolds throughout the infant's recovery period. Disrupted CBF leads in sequence to the phase of primary phase energy failure, the immediate reperfusion period, the latent phase and finally, the secondary phase of energy failure (Figure 1) .
The initial response of the fetus to a hypoxic-ischemic event is preservation of CBF by 1. cerebral vasodilatation (secondary to hypercapnia and hypoxemia) 2. loss of cerebral autoregulation 3. redistribution of organ blood flow.
Increased CBF, however, is quickly superseded by an impairment in CBF, with concomitant bradycardia and decreased blood pressure. 51 At the cellular level, the disruption of CBF leads to a primary energy failure, and the activation of cell death processes. 52 Energy failure induced by severe, acute asphyxia rapidly results in neuronal death via necrosis, characterized by plasma membrane swelling and rupture, which releases intracellular toxins into the local milieu. In contrast, energy loss following less severe or prolonged hypoxic-ischemic insult leads to apoptosis, a slower form of neuronal death often described as cell suicide. 53 During primary-phase energy failure, decreased levels of high-energy phosphate compounds, such as phosphocreatine (PCr), the principal storage form of high-energy phosphate, as well as adenosine triphosphate (ATP) promote mitochondrial dysfunction (Figure 2) . Under healthy conditions, the cell's ATP is mitochondrially-generated via oxidative phosphorylation, which is tightly connected with glucose metabolism. However, following energy failure, ATP production relies primarily on anerobic glycolysis. 54 A critical function of ATP is to maintain sodium (Na þ ), potassium (K þ ) and calcium (Ca 2 þ ) ionic gradients across membranes. 55 Following ATP loss, K þ leaks out of the affected cell, inducing depolarization and a massive release of glutamate, an excitatory amino acid. 56 Glutamate accumulates in the proximal synapses partly owing to decreased glutamate removal from the synapses by ATP-dependent glial glutamate transporters. 57 The accumulated glutamate overstimulates the NMDA receptors resulting in a rapid influx of Ca 2 þ into the intracellular space. The type of cell death that follows excessive Ca 2 þ influx is concentration-dependent; necrosis requires higher levels of intracellular Ca 2 þ than apoptosis. 58 Thus, through this glutamate-mediated neurodegenerative process, primary energy failure of energy-dependent membrane ion pumps, if sustained can activate cell death pathways before restoration of CBF.
The return of CBF demarcates the immediate reperfusion period. This period is characterized by normal blood pressure and intracellular pH, a transient improvement in cytotoxic edema and an absence of seizures. 59, 60 Experimental animal models suggest that the immediate reperfusion period rapidly transitions into the latent phase during which electroencephalographic (EEG) intensity is depressed. Within the cell, mitochondrial metabolism is nearly restored. 9, 61 Neuroprotective strategies are most effective if implemented during the first 6 hours following reperfusion. 59, 62 Following this temporal window, however, the affected infant experiences a second phase of energy failure. 59 Once again, levels of ATP as well as PCr decrease, whereas cytotoxic edema increases. 60, 63 Unlike the primary-phase energy failure, intracellular pH remains unchanged and the infant's cardiorespiratory status is usually stable. 63 The cellular response to secondary phase energy failure is similar to that of the primary phase energy failure in that excitatory amino acids are released from cells, leading to necrotic and apoptotic cell death. Much of the cell death is delayed, occurring slowly (hours to days) during the infant's recovery period. 64 The severity of the secondary-phase energy failure is strongly correlated with adverse neurodevelopmental outcomes at 1 and four years of age. 65 CBF increases during the phase of secondary energy failure and the infant begins to experience seizures. 59 In general, early seizures prognosticate poor long-term neurodevelopmental outcome.
The roles of the inflammatory response and maternal infection in HIE Factors that potentially contribute to HIE include the action of inflammatory cytokines, and maternal infection during gestation. Although the mechanisms by which these factors promote neuronal damage and death are not explicitly known, clinical studies and animal models have indicated their predominance in the development of HIE.
Despite multiple elegant studies, the complex relationships between cytokines and HIE remain poorly defined. Patterns and timing of cytokine expression are highly variable owing to factors such as maternal infection, ischemic preconditioning and developmental stage of the infant. 66, 67 As the infant's cytokine milieu may exacerbate or prevent hypoxic-ischemic damage, the variability of cytokine expression poses a considerable challenge to predicting long-term outcome following asphyxiation. Studies exploring the roles of interleukin-1b (IL-1 b), IL-6, and tumor necrosis factor-a (TNF-a) in HIE have shown that, within 24 hours, levels of these inflammatory mediators significantly increase in the cerebrospinal fluid (CSF) and serum of affected term and near-term infants.
68,69 IL-1 b and TNF-a are most likely produced within the brain, because the ratio of CSF to serum concentrations in these infants is 4.28 and 1.96, respectively. 68, 70 Studies using animal models of HIE suggest that proinflammatory cytokines exacerbate glutamate-induced neurodegeneration. IL-1b and IL-6 enhance NMDA receptor-mediated Ca 2 þ influx in developing neurons. [71] [72] [73] TNF-a can promote excitatory neuronal death by inhibiting glutamate uptake. 74 In a neonatal model of moderate transient focal cerebral ischemia, deficiency of IL-1b converting enzyme, the activator of IL-1b, or treatment with IL-1b receptor antagonist lessened hypoxic-ischemic injury. 75, 76 These studies suggest that IL-1b is a major contributor to HIE. However, the role of TNF-a in HIE appears to be more complicated. Inhibition of TNF-a activity in a rat HIE model is neuroprotective in the striatum, yet neurotoxic in the hippocampus. 77 In addition, neuronal damage caused by middle cerebral artery occlusion is exacerbated in TNF receptor-deficient mice relative to wild-type controls. 78 The latter study suggests that TNF-a may contribute to neurodegeneration during early stages of hypoxic-ischemic brain injury, but plays a major role in neuroprotection and repair during the later stages of recovery. Finally, maternal infection during gestation has shown to be a risk factor for CP in term infants in a large population-based case-control study. 79 Animal models of HIE suggest that intrauterine infection sensitizes the developing brain to damage initiated by intrapartum CBF changes.
80-82
Classification of HIE and long-term outcome The duration and severity of the intrapartum hypoxic-ischemic event appears to correlate with the regional distribution of brain injury and long-term outcome. The most common types of injury induced by hypoxic ischemic insult of the term or near-term infant are parasagittal cerebral (or watershed injury) and basal ganglia/ thalamus injury. 83 Parasagittal cerebral injury is a result of damage to the boundary zones of the cortex and subcortical white matter. This most common type of injury is caused by prolonged and partial asphyxia. In the more severe cases, cortical gray matter is also damaged. Recent data suggest that parasagittal cerebral injury can induce cognitive impairments without observable motor impairments. Additionally, infants with watershed predominant damage tend to have lower birth weights. 83 In contrast, basal ganglia/thalamus injuries primarily affect the basal ganglia and thalamus with little damage to the cerebral cortex. Usually this pattern of damage is caused by acute, near-total asphyxia. In very severe cases, the total cortex, as well as the cerebellar vermis, is injured. 84 Infants with basal ganglia/ thalamus injury are more commonly delivered by emergent Cesarean section, and usually need more intense resuscitation. 83 Relative to watershed injury, seizures and encephalopathy are greater for this type of injury. Long-term sequelae of basal ganglia/ thalamus injury are cognitive deficits, rigidity, seizures, severe upper extremity impairment and motor speech impairment. 83, 85 Neuroprotection and hypothermia Pharmacology of neuroprotection with hypothermia Modest systemic or selective hypothermia of the brain by as little as 2-41C has been shown to reduce the extent of tissue injury in experimental as well as human studies after events such as stroke, trauma or cardiac arrest. 9,86 -97 Before initiating hypothermia as a treatment strategy in newborn infants with HIE several factors determining effective neuroprotection with hypothermia need to be considered: duration of therapy-brief versus prolonged, timing for initiation of therapy, degree of cooling and method of achieving hypothermia.
Duration of therapy: brief versus prolonged. Brief periods (0.5-3 h) of mild to moderate hypothermia immediately after hypoxic-ischemic injury results in only partial or temporary neuroprotection in most experimental animals. 9, [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] Studies suggest that such brief cooling may be most effective only after relatively mild insults. [98] [99] [100] Prolonging hypothermia from 24 to 72 h after hypoxia-ischemia attenuates brain damage and improves behavioral performance. 9, 90, 95 More critically, this protection appears to be lost if hypothermia is delayed by as little as 15-45 min after the primary insult. [101] [102] [103] Such an extreme sensitivity to delay is consistent with the hypothesis that hypothermia might act to suppress reperfusion injury. 104 Alternatively, this strategy may effectively represent intervention at the end of the primary-phase of energy failure, when cerebrovascular perfusion is being re-established and cell function is starting to recover. 9 A more recent approach has been to try to suppress the secondary encephalopathic processes by maintaining hypothermia throughout the course of the secondary phase of energy failure. Supporting this concept, extended periods of cooling, of between 5 and 72 hours, appear to be more consistently effective.
100,105-108
Timing for initiation of therapy. The sooner hypothermia can be initiated, the more likely it is to be successful. Hypothermia is most effective when administered during the latent phase of the injury, before the onset of the secondary phase of energy failure. 109 Short durations of cooling are associated with extreme sensitivity to delay. In contrast, extended periods of hypothermia may be effective after significant delays between the primary insult and the start of cooling. Moderate selective cerebral hypothermia initiated within 90 min and continued until 72 hours after ischemia has been shown to prevent secondary cytotoxic edema, and improve electroencephalographic recovery in the fetal sheep. 9 There was also concomitant substantial reduction in parasagittal cortical infarction and improvement in neuronal loss scores in all regions assessed. Though markedly reduced, significant neuroprotection was still observed when the delay was extended to 5.5 hours. 90 Data from various adult models also support this concept. 86, 88, 89 These studies performed at various stages of maturation in a range of species strongly support several conclusions. Firstly, that a sufficient duration of cooling is required in relation to the type and severity of the primary insult, suggesting that such delayed cooling is acting via sustained suppression of cytotoxic events in the secondary phase of energy failure. Secondly, that although the window of opportunity for prolonged cooling after global insults (or reversible focal injury) may be up to 6 hours or even longer in some circumstances, the degree of neuroprotection progressively declines if cooling is initiated more than a few hours post-insult.
Degree of cooling. Moderate hypothermia at brain temperatures of 32-341C initiated immediately or within a few hours after reperfusion and continued for 24-72 hours has been shown to favorably affect outcome in newborn and adult animals. 9, 90 It is highly likely that there is a critical depth of hypothermia required for effective neuronal rescue. In turn, the required threshold may be modified by the severity of the initial insult, how soon hypothermia is started after the insult and how long cooling is continued. 99, 100, 107 There is an obvious trade-off between the adverse systemic effects of cooling, which increase markedly below a core temperature of 32-341C, and the potential cerebral benefit. The potential systemic adverse effects of hypothermia in newborn infants include increased mortality particularly in preterm infant, hypoglycemia, reduction of cardiac contractility and cardiac output, ventilation-perfusion mismatch, increased blood viscosity, coagulopathy, acid-base and electrolyte imbalance and an increased risk of infections. 95, 110 Method of achieving hypothermia. Selective brain cooling is attractive as it can provide adequate neuroprotection with minimal risk of systemic adverse effects, but it is associated with differential gradients within the brain. 111 In contrast, total body cooling is more likely to be associated with adverse effects, but causes fewer gradients within the brain. In a small, observational study, Rutherford et al. 112 have recently reported a decreased incidence of severe cortical lesions on magnetic resonance imaging in infants treated with selective head cooling and modest systemic hypothermia, compared to those with whole-body cooling.
Protective mechanisms Moderate (35.51C) and profound (21 and 281C) hypothermia maintained during the hypoxic-ischemic insult results in absence of histologic injury and preservation of motor function. 88, 94, [113] [114] [115] Postischemic hypothermia is also neuroprotective through the reduction of secondary cortical cytotoxic edema, cortical infarction and neuronal loss. 9, [116] [117] [118] [119] The most important target for hypothermia is the reduction in cerebral energy metabolism. Cooling the brain during hypoxia-ischemia ameliorates the change in energy metabolites resulting in less brain damage. 113 A potential mechanism for preservation of energy metabolites is a decrease in brain energy utilization rate and consequent preservation of brain ATP levels. 120 The neuroprotection afforded by hypothermia may be through the inhibition of apoptosis; 121, 122 studies have shown a reduction in caspase-3 like activity and a reduction in the phosphorylation of Akt. 123, 124 Hypothermia has also been shown to inhibit glutamate release, preserve endogenous antioxidants, reduce nitric oxide production, 125 decrease free radical production, improve protein synthesis, preserve N-acetylaspartate and reduced glutathione levels, 126 prevent blood-brain barrier disruption and lessen brain edema.
Clinical trials Pilot trials. Although Westin et al. 127 first reported the beneficial effects of hypothermia in perinatal asphyxia in 1955, only in the past decade have systematic studies been performed to address the efficacy and safety of hypothermia in HIE. 10, [128] [129] [130] [131] These studies described the methodology for cooling the head or the whole body for up to 72 hours without serious short-term complications. The results from these studies demonstrated that although bradycardia occurred commonly, other acute complications did not occur with mild hypothermia for 72 hours. In a multicenter, randomized, controlled, pilot trial of whole-body cooling to a rectal temperature of 331±0.51C for 48 h in neonates (n ¼ 65) following a hypoxicischemic event, Eicher et al. 131 reported a lower combined outcome of death or severe neuromotor disability in the hypothermia group (52%) than the normothermia group (84%). The mortality was 31% in the hypothermia group as compared to 42% in the control group. There was higher incidence of bradycardia and greater use of inotropic agents in the hypothermia group as a compared to the control subjects. The cumulative evidence from the numerous animal studies and reassuring results of short-term safety and feasibility studies in human infants with HIE fostered the development of larger randomized controlled trials.
Large-scale clinical trials
Two large randomized, multicenter trials in term infants with HIE, using either selective or systemic modest hypothermia have recently been completed. The first study (Cool-Cap Trial) 1 utilized selective head cooling and mild systemic hypothermia, and included 234 infants with moderate to severe neonatal encephalopathy and abnormal amplitude-integrated electroencephalogram (aEEG). The stepwise biochemical/clinical, neurologic and EEG criteria for entry were as follows: greater than 36 weeks gestation; an Apgar score less than 5 at 10 min after birth or a continued need for resuscitation at 10 min after birth; or a pH less than 7.0 or base deficit greater than 16 mmol/l in the umbilical blood or venous blood sample within 60 min of birth; and a modified Sarnat score and aEEG criteria consistent with a diagnosis of moderate to severe HIE. Infants were randomized to head cooling and mild systemic hypothermia (rectal temperature 34-351C) or normothermia for 72 hours, and were then rewarmed at a rate of less than 0.51C/ hours. The primary outcome was death or severe disability at 18 months. Of the 218 infants (93%), 66% of the controls and 55% of the cooled infants had an unfavorable primary outcome (odds ratio, 0.61; 95% CI, 0.32-1.09; P ¼ 0.1). A logistic regression analysis controlling for baseline aEEG severity, presence of seizures and age at randomization indicated a possible treatment effect from hypothermia (odds ratio, 0.57; 95% CI, 0.32-1.01; P ¼ 0.05). There were no differences in frequency of clinically important complications. In a predefined subgroup analysis, head cooling was beneficial to those with less severe pre-randomization aEEG changes (n ¼ 172; odds ratio, 0.42; 95% CI, 0.22-0.80; P ¼ 0.009) as compared to those with severe changes (n ¼ 46). On further post hoc analysis, when baseline clinical severity was added to the regression model, a significant protective effect from hypothermia was observed for the entire cohort (odds ratio 0.52, 95% CI, 0.28-0.70; P ¼ 0.04). 132 In the second large randomized controlled clinical trial, Shankaran et al.
2 tested the effect of whole-body hypothermia in moderate to severe HIE. The study enrolled 208 infants X36 weeks gestational age, admitted to a neonatal intensive care unit at less than 6 hours of age, with either a diagnosis of encephalopathy or poor respiratory effort at birth requiring resuscitation. Eligibility criteria were similar to the Cool Cap Trial and included a pH of 7.0 or less or a base deficit of 16 mmol/l or more in a sample of umbilical cord blood or any blood during the first hour after birth. If, during this interval, the pH was between 7.01 and 7.15, a base deficit was between 10 and 15.9 mmol/l, or a blood gas level was not available, the presence of additional criteria could qualify the patient for consideration. These additional criteria included the existence of an acute perinatal event (like late or variable decelerations, cord rupture, cord prolapse, uterine rupture, maternal trauma, hemorrhage of cardiorespiratory arrest) and either a 10-min Apgar score of less than 5 or assisted ventilation initiated at birth and continued for at least 10 minutes. Once these criteria were met, all infants underwent a standardized neurologic evaluation performed by a certified examiner. Infants were eligible candidates when seizures or moderate or severe encephalopathy was present; no aEEG was utilized. Infants randomized to whole-body hypothermia (n ¼ 102) were placed on a precooled blanket (51C) connected to a cooling system and the esophageal temperature was reduced to and maintained at 33.5±0.51C for 72 hours followed by rewarming by on-site research personnel using the Cincinnati Sub-Zero System, whereas the control infants (n ¼ 106) were given standard intensive care. The primary outcome was a combined end point of death or moderate to severe disability at 18-22 months of age. Of the 205 infants (98%), infants who underwent hypothermia had significantly lower incidence of death or moderate/severe disability at 18 months (44% versus 66%; relative risk, 0.72; 95% CI, 0.54-0.95; P ¼ 0.01), indicating six infants need to be treated on average to result in one additional infant with a better outcome. There were no differences between the two groups in the incidence of mortality alone, disabling cerebral palsy, blindness, severe hearing impairment and Bayley MDI or PDI scores.
Other ongoing trials
In the Total Body Cooling Trial (TOBY trial ) from England, infants with moderate-to-severe HIE are randomized to receive whole-body cooling or standard intensive care. The study finished its enrollment of 239 infants in November of 2006. As the study design and the entry criteria for this trial are similar to those of the CoolCap trial, upon completion, the findings from the TOBY trial can be effectively compared with those of CoolCap to assess the relative benefits from whole-body versus selective head cooling in HIE.
The ICE (Infant Cooling Evaluation) trial aims to enroll infants from a wide geographic region (15 centers in Australia, Canada and New Zealand) using simplified protocols. 133 Hypothermia is achieved by turning off the ambient heating systems and by applying 'Hot-Cold' gel packs (at 101C) around the infant's head and over the chest, so that the rectal temperature is reduced to 33-341C. The investigators plan to enroll 276 infants in this ongoing trial.
Conclusion
HIE remains a challenging problem for all clinicians. Only three randomized clinical trials are available at this time to guide clinical decisions (the TOBY and ICE studies are in progress). Edwards and Azzopardi 134 have recently published a speculative meta-analysis of these three studies. The data suggest that mild hypothermia is associated with a significant reduction in death or severe disability. However, one must be cautious in accepting the results of this analysis considering the marked heterogeneity of the studies included. Currently, there are too many unanswered questions to make hypothermia a standard of care:
1. Are there important clinical differences between selective head cooling and total body cooling? 2. Can infants who will benefit from cooling be accurately identified? 3. What degree of hypothermia offers the greatest degree of neuroprotection? 4. How long should cooling be continued? 5. If cooling is continued for longer than 72 hours, will it benefit infants who are enrolled after 6 hours? 6. Will the benefits of cooling be evident when the current study subjects reach school age?
It is the opinion of these authors that the use of hypothermia should remain a research tool. However, it will be difficult to regulate the introduction of cooling into clinical practice. Given the potential risks of cooling and re-warming, it is important for centers that wish to make it standard of care to have their physicians trained in the use of total body or selective head cooling. All cooled infants should be entered into a registry and it is the responsibility of each center to provide long-term follow-up. Finally, we are just entering the era in which hypothermia will be used with other interventions. 135 It is likely that combined therapies will offer significantly greater degrees of neuroprotection.
